Share

April 2014; 4 (2) Guideline Perspective

Stroke prevention in atrial fibrillation

Commentary regarding the AAN's evidence-based guideline update

Robert G. Hart, John W. Eikelboom
First published February 24, 2014, DOI: https://doi.org/10.1212/CPJ.0000000000000003
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
2326

Share

Article Information

vol. 4 no. 2 96-98
DOI: 
https://doi.org/10.1212/CPJ.0000000000000003
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • First Published February 24, 2014.

Article Versions

Copyright & Usage: 
© 2014 American Academy of Neurology

Author Disclosures

    1. Robert G. Hart, MD and
    2. John W. Eikelboom, MBBS
  1. Robert G. Hart, MD and
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. I received research support from Bayer Pharmaceuticals (but no personal recompense).

    Research Support, Government Entities:

    1. National Institute of Neurological Disorder and Stroke, co-principal investigator for the SPS3 randomized trial, 2003-2010.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. John W. Eikelboom, MBBS
    3. Scientific Advisory Boards:

    1. 1. DSMB Rocket-AF study, Hokusai study, 2. Advisory Boards, Bayer, BI BMS/Pfizer Daiichi Sankyo

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Consulting fees and honoraria: Astra-Zeneca, Bayer Boehringer-Ingelheim, Bristol-Myer-Squibb, Daiichi-Sankyo, Eli-Lilly, Glaxo-Smith-Kline, Pfizer, Janssen, Sanofi-Aventis

    Editorial Boards:

    1. Thrombosis and Haemostasis, Editorial Board Member

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Consulting fees and honoraria: Astra-Zeneca, Bayer Boehringer-Ingelheim, Bristol-Myer-Squibb, Daiichi-Sankyo, Eli-Lilly, Glaxo-Smith-Kline, Pfizer, Janssen, Sanofi-Aventis

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. Yes, I use oral anticoagulants on a regular basis for treatment of venous thromboembolism and atrial fibrillation. Thrombosis Unit, Hamilton General Hospital, 25%

    Research Support, Commercial Entities:

    1. Grants and in-kind support: Astra-Zeneca, Bayer, Boehringer-Ingelheim, Bristol-Myer-Squibb, Glaxo-Smith-Kline, Pfizer, Janssen, Sanofi-Aventis

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Canadian Institute for Health Research, Heart and Stroke Foundation of Ontario, National Health and Medical Research Council, New Investigator Fund, Hamilton Health Sciences

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. McMaster University/Population Health Research Institute, Hamilton Health Sciences, Hamilton, Canada.
  1. Correspondence to:
    robert.hart{at}phri.ca
View Full Text

Article usage

Article usage: February 2014 to August 2023

AbstractFullPdfSource
Feb 2014305164Highwire
Mar 20141930548Highwire
Apr 2014668102354Highwire
May 201424342109Highwire
Jun 2014962751Highwire
Jul 201474832Highwire
Aug 201454321Highwire
Sep 201436521Highwire
Oct 201430319Highwire
Nov 201451322Highwire
Dec 20149715Highwire
Jan 201529225Highwire
Jan 20150103pmc
Feb 201527410Highwire
Feb 20150157pmc
Mar 20152133Highwire
Mar 20150178pmc
Apr 20151659Highwire
Apr 20150106pmc
May 201520213Highwire
May 2015063pmc
Jun 201533214Highwire
Jun 2015034pmc
Jul 201511110Highwire
Jul 20150134pmc
Aug 20151048Highwire
Aug 20150166pmc
Sep 201526416Highwire
Sep 20150227pmc
Oct 201519917Highwire
Oct 20150811pmc
Nov 20153616Highwire
Nov 20150104pmc
Dec 20152437Highwire
Dec 2015096pmc
Jan 201634415Highwire
Jan 2016073pmc
Feb 2016727Highwire
Feb 2016040pmc
Mar 201618023Highwire
Mar 20160134pmc
Apr 201617356Highwire
Apr 2016093pmc
May 201631411Highwire
May 2016086pmc
Jun 201630410Highwire
Jun 2016044pmc
Jul 201624411Highwire
Jul 2016050pmc
Aug 20161859Highwire
Aug 2016031pmc
Sep 20161824Highwire
Sep 2016040pmc
Oct 201617614Highwire
Oct 2016021pmc
Nov 20162077Highwire
Nov 2016093pmc
Dec 20161753Highwire
Dec 2016050pmc
Jan 20172498Highwire
Jan 20170155pmc
Feb 20172312Highwire
Feb 20170156pmc
Mar 20171526Highwire
Mar 20170194pmc
Apr 20171014Highwire
Apr 2017177pmc
May 20171125Highwire
May 201731722pmc
Jun 20171308Highwire
Jun 201751718pmc
Jul 2017907Highwire
Jul 201741113pmc
Aug 2017815Highwire
Aug 201731213pmc
Sep 2017829Highwire
Sep 201721415pmc
Oct 20174023Highwire
Oct 201711515pmc
Nov 20171953Highwire
Nov 201721111pmc
Dec 2017080Highwire
Jan 20182113Highwire
Feb 20183142Highwire
Mar 20182173Highwire
Apr 20183158Highwire
Apr 20182913pmc
May 20186402Highwire
Jun 201811413Highwire
Jun 2018022pmc
Jul 201810342Highwire
Aug 20186291Highwire
Aug 2018155pmc
Sep 20188346Highwire
Oct 201818263Highwire
Nov 201815353Highwire
Dec 201812482Highwire
Jan 201951185Highwire
Feb 201927110Highwire
Mar 20192265Highwire
Apr 20192106Highwire
May 201911439Highwire
Jun 201931812Highwire
Jul 20191195Highwire
Aug 20192148Highwire
Sep 2019288Highwire
Oct 2019394Highwire
Nov 20192105Highwire
Dec 20192108Highwire
Jan 20202114Highwire
Feb 2020585Highwire
Mar 2020244Highwire
Apr 2020062Highwire
May 2020073Highwire
Jun 2020074Highwire
Jul 2020065Highwire
Aug 2020132Highwire
Sep 20207154Highwire
Oct 20203127Highwire
Nov 2020089Highwire
Dec 20203128Highwire
Jan 2021276Highwire
Feb 2021245Highwire
Mar 20212134Highwire
Apr 20211613Highwire
May 2021074Highwire
Jun 2021272Highwire
Jul 2021379Highwire
Aug 20215196Highwire
Sep 2021045Highwire
Oct 202111518Highwire
Nov 20210313Highwire
Dec 2021062Highwire
Jan 20221184Highwire
Feb 20221133Highwire
Mar 20224123Highwire
Apr 20221125Highwire
May 20223910Highwire
Jun 2022032Highwire
Jul 2022246Highwire
Aug 2022164Highwire
Sep 20222169Highwire
Oct 20223118Highwire
Nov 202254310Highwire
Dec 20222155Highwire
Jan 20232199Highwire
Feb 20231154Highwire
Mar 2023071Highwire
Apr 2023033Highwire
May 2023144Highwire
Jun 2023161Highwire
Jul 2023177Highwire
Aug 2023044Highwire

The Nerve!: Rapid online correspondence

Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Alert Me

Recommended articles